[Clinical Features and Prognostic of Patients with Primary Central Nervous System Lymphoma]
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Primary central nervous system lymphoma (PCNSL) patients treated with novel BTKi medications show improved survival. Deep brain infiltration is a poor prognostic factor for progression-free survival in PCNSL.
Area Of Science
- Neuro-oncology
- Hematology
- Clinical Medicine
Context
- Primary central nervous system lymphoma (PCNSL) is a rare and aggressive non-Hodgkin lymphoma.
- Accurate prognostic factors and effective treatment strategies are crucial for improving patient outcomes.
Purpose
- To investigate the clinical characteristics, treatment responses, and prognostic factors of patients diagnosed with PCNSL.
- To evaluate the efficacy of different treatment regimens, including novel agents like BTKi.
Summary
- A retrospective analysis of 46 PCNSL patients revealed diffuse large B-cell lymphoma (DLBCL) as the predominant type, with a median age of 54.
- Overall response rate (ORR) was 63.9% and complete response (CR) rate was 47.2%. Two-year progression-free survival (PFS) and overall survival (OS) rates were 52.2% and 68.9%, respectively.
- Deep brain infiltration was associated with adverse PFS (P=0.032), and treatment regimen with adverse OS (P=0.025). Novel BTKi-containing regimens showed promise for relapse/refractory PCNSL.
Impact
- Treatment modalities are independent predictors of OS, while deep brain infiltration predicts poor PFS.
- Novel medications like BTKi demonstrate therapeutic potential for high-risk and relapsed/refractory PCNSL patients.
- Findings support personalized treatment approaches and highlight BTKi as a promising first-line therapy option.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.